
Delighted that our study mapping the #proteome in #SLE is now published in @JCI_insight . Great work from the team especially grad student Geoffrey Leung insight.jci.org/articles/vie…

@imperialNHLI Prof of Interstitial lung disease | @asthmalunguk Prof of Respiratory Research | Director NIHR CRF @RBandH and #IPF doctor. Working to #cureIPF

Delighted that our study mapping the #proteome in #SLE is now published in @JCI_insight . Great work from the team especially grad student Geoffrey Leung insight.jci.org/articles/vie…

Join Strados Labs at #ATS2026 for an Innovation Hub session presented by @drphilmol on cough in respiratory diseases—spanning clinical trials & patient care. May 17 | 11:55–12:15 | Innovation Hub 3 Add to calendar: addevent.com/event/6j9qqls7b… #respiratoryresearch #clinicaltrials

Join the European Respiratory Society (ERS) this March for the Academy of interstitial lung diseases! This ERS course will provide updates on diagnostic procedures, specific diseases and treatment! Learn more and register: ersnet.org/events/academy-of…

📊 Research Summary: Higher doses of nalbuphine ER led to greater cough reduction in idiopathic pulmonary fibrosis; adverse events were consistent with those expected for opioid-class medications. ja.ma/3ZbF1OZ

Trevi is pleased to announce the publication of data from the Phase 2b IPF chronic cough trial of nalbuphine ER in the Journal of the American Medical Association (JAMA). Read the press release and access the publication here: ow.ly/BORg50Y1jS3 @drphilmol @JAMA_current

Nice to see a joint call for papers from @LancetRespirMed and @ThoraxBMJ for the @BTSrespiratory winter meeting Deadline 30th June. Come on brilliant bronchiectasis and airways colleagues- lets get some great papers in the queue for this 😀 thelancet.com/journals/lanre…

We have a one year clinical fellow post (maternity cover) available. Study looking at human viral challenge in bronchiectasis. Would suit IMT or specialist respiratory trainee. Details: imperial.ac.uk/jobs/search-j… Grateful for retweets. Please DM/email if interested.

Congratulations to @RBandH for recruiting two participants to the CHORUS Trial in December 🥳

Ahead of Respiratory Conference on 13 March, we’re featuring some of the fantastic respiratory medical experts who’ll speak at the event. Speakers will include @drphilmol in session one covering ILD & @RichardJHewitt focusing on ILAs in session 3. Book at: rcp.sg/respc

If you missed our onsite event in March, why not register for the virtual academy of interstitial lung diseases? This course will cover ILD diagnosis, plus current, novel and future therapies and more! Register now: bit.ly/4izseNx

Welcome to @MFTnhs who opened to recruitment today! 🥳

The weekly cancer MDT meeting can cause treatment delays, result in poor quality decisions, and waste clinicians’ time, say @tomroques and colleagues. It’s time for a fresh approach bmj.com/content/391/bmj.r224…

In the IMPALA-2 phase 3 trial, the inhaled recombinant human GM-CSF molgramostim improved pulmonary gas transfer in patients with autoimmune pulmonary alveolar proteinosis. Full trial results and Research Summary: nej.md/476PdNU

📢 Save the date! Join us on 10 Sept 2025 for an #ILDIN webinar with @drphilmol “From Calm to Crisis: ILD Acute Exacerbations” ➡️ For ILD-IN members. Registration info coming soon via email. #ILD #ERS #LungHealth
It is a great privilege to have @drphilmol as guest speaker for the first in our exciting webinar series on 10th September. Access details have been emailed to ILD-IN members. Don't miss this fantastic opportunity to hear Prof Molyneaux share his expertise in ILD.

Editorial: The Future of academic respiratory medicine - near crisis point. thorax.bmj.com/content/80/9/…
